Identification and Characterization of Multiple TRIM Proteins That Inhibit Hepatitis B Virus Transcription

PLoS ONE

Volumn 8, Issue 8, 2013, Pages

  Zhang, Shijian ^a,b   Guo, Ju Tao ^c   Wu, Jim Z ^a   Yang, Guang ^a  

^a Roche R and D Center China Ltd   (China)

^b FUDAN UNIVERSITY   (China)

^c DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; MICROORGANISM PROTEIN; TRANSCRIPTION FACTOR; TRIPARTITE MOTIF PROTEIN; TRIPARTITE MOTIF PROTEIN 41; UBIQUITIN PROTEIN LIGASE E3; UNCLASSIFIED DRUG; VIRUS DNA; VIRUS PROTEIN;

ARTICLE; CONTROLLED STUDY; DNA SYNTHESIS; ENZYME ACTIVITY; GENE EXPRESSION; GENOME ANALYSIS; HEPATITIS B VIRUS; HUMAN; HUMAN CELL; INNATE IMMUNITY; MOLECULAR DYNAMICS; NONHUMAN; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; VIRUS ASSEMBLY; VIRUS CAPSID; VIRUS GENOME; VIRUS INHIBITION; VIRUS REPLICATION; VIRUS TRANSCRIPTION; VIRUS VIRULENCE;

CARRIER PROTEINS; GENOME, VIRAL; HEP G2 CELLS; HEPATITIS B VIRUS; HUMANS; IMMUNITY, INNATE; PROMOTER REGIONS, GENETIC; TRANSCRIPTION, GENETIC; UBIQUITIN-PROTEIN LIGASES; VIRUS REPLICATION;

EID: 84881021016     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0070001     Document Type: Article

References (58)

1. Hatakeyama S, (2011) TRIM proteins and cancer. Nat Rev Cancer 11: 792-804.
2. McNab FW, Rajsbaum R, Stoye JP, O'Garra A, (2011) Tripartite-motif proteins and innate immune regulation. Curr Opin Immunol 23: 46-56.
3. Munir M, (2010) TRIM proteins: another class of viral victims. Sci Signal 3: jc2.
4. Ozato K, Shin DM, Chang TH, Morse HC, 3rd (2008) TRIM family proteins and their emerging roles in innate immunity. Nat Rev Immunol 8: 849-860.
5. Carthagena L, Bergamaschi A, Luna JM, David A, Uchil PD, et al. (2009) Human TRIM gene expression in response to interferons. PLoS One 4: e4894.
6. Hatziioannou T, Perez-Caballero D, Yang A, Cowan S, Bieniasz PD, (2004) Retrovirus resistance factors Ref1 and Lv1 are species-specific variants of TRIM5alpha. Proc Natl Acad Sci U S A 101: 10774-10779.
7. Perron MJ, Stremlau M, Song B, Ulm W, Mulligan RC, et al. (2004) TRIM5alpha mediates the postentry block to N-tropic murine leukemia viruses in human cells. Proc Natl Acad Sci U S A 101: 11827-11832.
8. Stremlau M, Owens CM, Perron MJ, Kiessling M, Autissier P, et al. (2004) The cytoplasmic body component TRIM5alpha restricts HIV-1 infection in Old World monkeys. Nature 427: 848-853.
9. Wolf D, Cammas F, Losson R, Goff SP, (2008) Primer binding site-dependent restriction of murine leukemia virus requires HP1 binding by TRIM28. J Virol 82: 4675-4679.
10. Taylor RT, Lubick KJ, Robertson SJ, Broughton JP, Bloom ME, et al. (2011) TRIM79alpha, an interferon-stimulated gene product, restricts tick-borne encephalitis virus replication by degrading the viral RNA polymerase. Cell Host Microbe 10: 185-196.
11. Gao B, Duan Z, Xu W, Xiong S, (2009) Tripartite motif-containing 22 inhibits the activity of hepatitis B virus core promoter, which is dependent on nuclear-located RING domain. Hepatology 50: 424-433.
12. Kajaste-Rudnitski A, Marelli SS, Pultrone C, Pertel T, Uchil PD, et al. (2011) TRIM22 inhibits HIV-1 transcription independently of its E3 ubiquitin ligase activity, Tat, and NF-kappaB-responsive long terminal repeat elements. J Virol 85: 5183-5196.
13. Wang J, Liu B, Wang N, Lee YM, Liu C, et al. (2011) TRIM56 is a virus- and interferon-inducible E3 ubiquitin ligase that restricts pestivirus infection. J Virol 85: 3733-3745.
14. Uchil PD, Quinlan BD, Chan WT, Luna JM, Mothes W, (2008) TRIM E3 ligases interfere with early and late stages of the retroviral life cycle. PLoS Pathog 4: e16.
15. Oke V, Wahren-Herlenius M, (2012) The immunobiology of Ro52 (TRIM21) in autoimmunity: a critical review. J Autoimmun 39: 77-82.
16. Gack MU, Shin YC, Joo CH, Urano T, Liang C, et al. (2007) TRIM25 RING-finger E3 ubiquitin ligase is essential for RIG-I-mediated antiviral activity. Nature 446: 916-920.
17. Shi M, Deng W, Bi E, Mao K, Ji Y, et al. (2008) TRIM30 alpha negatively regulates TLR-mediated NF-kappa B activation by targeting TAB2 and TAB3 for degradation. Nat Immunol 9: 369-377.
18. Tsuchida T, Zou J, Saitoh T, Kumar H, Abe T, et al. (2010) The ubiquitin ligase TRIM56 regulates innate immune responses to intracellular double-stranded DNA. Immunity 33: 765-776.
19. Shen Y, Li NL, Wang J, Liu B, Lester S, et al. (2012) TRIM56 is an essential component of the TLR3 antiviral signaling pathway. J Biol Chem 287: 36404-36413.
20. Versteeg GA, Rajsbaum R, Sanchez-Aparicio MT, Maestre AM, Valdiviezo J, et al. (2013) The E3-Ligase TRIM Family of Proteins Regulates Signaling Pathways Triggered by Innate Immune Pattern-Recognition Receptors. Immunity 38: 384-398.
21. Uchil PD, Hinz A, Siegel S, Coenen-Stass A, Pertel T, et al. (2013) TRIM protein-mediated regulation of inflammatory and innate immune signaling and its association with antiretroviral activity. J Virol 87: 257-272.
22. Lee WM, (1997) Hepatitis B virus infection. N Engl J Med 337: 1733-1745.
23. Chisari FV, Ferrari C, (1995) Hepatitis B virus immunopathogenesis. Annu Rev Immunol 13: 29-60.
24. Guidotti LG, Chisari FV, (2006) Immunobiology and pathogenesis of viral hepatitis. Annu Rev Pathol 1: 23-61.
25. Perrillo R, (2009) Benefits and risks of interferon therapy for hepatitis B. Hepatology. 49: S103-111.
26. Janssen HL, van Zonneveld M, Senturk H, Zeuzem S, Akarca US, et al. (2005) Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet 365: 123-129.
27. Lau GK, Piratvisuth T, Luo KX, Marcellin P, Thongsawat S, et al. (2005) Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med. 352: 2682-2695.
28. Guo H, Jiang D, Zhou T, Cuconati A, Block TM, et al. (2007) Characterization of the intracellular deproteinized relaxed circular DNA of hepatitis B virus: an intermediate of covalently closed circular DNA formation. J Virol 81: 12472-12484.
29. Shi L, Li S, Shen F, Li H, Qian S, et al. (2012) Characterization of nucleosome positioning in hepadnaviral covalently closed circular DNA minichromosomes. J Virol 86: 10059-10069.
30. Mao R, Zhang J, Jiang D, Cai D, Levy JM, et al. (2011) Indoleamine 2,3-dioxygenase mediates the antiviral effect of gamma interferon against hepatitis B virus in human hepatocyte-derived cells. J Virol 85: 1048-1057.
31. Quasdorff M, Protzer U, (2010) Control of hepatitis B virus at the level of transcription. J Viral Hepat 17: 527-536.
32. Moolla N, Kew M, Arbuthnot P, (2002) Regulatory elements of hepatitis B virus transcription. J Viral Hepat 9: 323-331.
33. Li M, Xie Y, Wu X, Kong Y, Wang Y, (1995) HNF3 binds and activates the second enhancer, ENII, of hepatitis B virus. Virology 214: 371-378.
34. Johnson JL, Raney AK, McLachlan A, (1995) Characterization of a functional hepatocyte nuclear factor 3 binding site in the hepatitis B virus nucleocapsid promoter. Virology 208: 147-158.
35. Raney AK, Johnson JL, Palmer CN, McLachlan A, (1997) Members of the nuclear receptor superfamily regulate transcription from the hepatitis B virus nucleocapsid promoter. J Virol 71: 1058-1071.
36. Banks KE, Anderson AL, Tang H, Hughes DE, Costa RH, et al. (2002) Hepatocyte nuclear factor 3beta inhibits hepatitis B virus replication in vivo. J Virol 76: 12974-12980.
37. Chen D, Gould C, Garza R, Gao T, Hampton RY, et al. (2007) Amplitude control of protein kinase C by RINCK, a novel E3 ubiquitin ligase. J Biol Chem 282: 33776-33787.
38. Tanaka M, Fukuda Y, Mashima K, Hanai R, (2005) Intracellular localization and domain organization of human TRIM41 proteins. Mol Biol Rep 32: 87-93.
39. Ruby T, Bed'Hom B, Wittzell H, Morin V, Oudin A, et al. (2005) Characterisation of a cluster of TRIM-B30.2 genes in the chicken MHC B locus. Immunogenetics 57: 116-128.
40. Acs G, Sells MA, Purcell RH, Price P, Engle R, et al. (1987) Hepatitis B virus produced by transfected Hep G2 cells causes hepatitis in chimpanzees. ProcNatlAcadSciUSA 84: 4641-4644.
41. Rowe HM, Kapopoulou A, Corsinotti A, Fasching L, Macfarlan TS, et al. (2013) TRIM28 repression of retrotransposon-based enhancers is necessary to preserve transcriptional dynamics in embryonic stem cells. Genome Res.
42. Zhao KW, Sikriwal D, Dong X, Guo P, Sun X, et al. (2011) Oestrogen causes degradation of KLF5 by inducing the E3 ubiquitin ligase EFP in ER-positive breast cancer cells. Biochem J 437: 323-333.
43. Zou W, Zhang DE, (2006) The interferon-inducible ubiquitin-protein isopeptide ligase (E3) EFP also functions as an ISG15 E3 ligase. J Biol Chem 281: 3989-3994.
44. Shimizu I, Kohno N, Tamaki K, Shono M, Huang HW, et al. (2007) Female hepatology: favorable role of estrogen in chronic liver disease with hepatitis B virus infection. World J Gastroenterol 13: 4295-4305.
45. Almog Y, Klein A, Adler R, Laub O, Tur-Kaspa R, (1992) Estrogen suppresses hepatitis B virus expression in male athymic mice transplanted with HBV transfected Hep G-2 cells. Antiviral Res 19: 285-293.
46. Wang SH, Yeh SH, Lin WH, Yeh KH, Yuan Q, et al. (2012) Estrogen receptor alpha represses transcription of HBV genes via interaction with hepatocyte nuclear factor 4alpha. Gastroenterology 142: 989-998 e984.
47. Guo H, Jiang D, Ma D, Chang J, Dougherty AM, et al. (2009) Activation of pattern recognition receptor-mediated innate immunity inhibits the replication of hepatitis B virus in human hepatocyte-derived cells. J Virol 83: 847-858.
48. Guidotti LG, Rochford R, Chung J, Shapiro M, Purcell R, et al. (1999) Viral clearance without destruction of infected cells during acute HBV infection [In Process Citation]. Science 284: 825-829.
49. Guidotti LG, Ishikawa T, Hobbs MV, Matzke B, Schreiber R, et al. (1996) Intracellular inactivation of the hepatitis B virus by cytotoxic T lymphocytes. Immunity 4: 25-36.
50. Guidotti LG, Ando K, Hobbs MV, Ishikawa T, Runkel L, et al. (1994) Cytotoxic T lymphocytes inhibit hepatitis B virus gene expression by a noncytolytic mechanism in transgenic mice. Proc Natl Acad Sci USA 91: 3764-3768.
51. Guo J-T, Zhou H, Liu C, Aldrich C, Saputelli J, et al. (2000) Apoptosis and regeneration of hepatocytes during recovery from transient hepadnavirus infection. J Virology 74: 1495-1505.
52. Jilbert AR, Wu TT, England JM, Hall PM, Carp NZ, et al. (1992) Rapid resolution of duck hepatitis B virus infections occurs after massive hepatocellular involvement. J Virol 66: 1377-1388.
53. Kajino K, Jilbert AR, Saputelli J, Aldrich CE, Cullen J, et al. (1994) Woodchuck hepatitis virus infections: very rapid recovery after a prolonged viremia and infection of virtually every hepatocyte. J Virol 68: 5792-5803.
54. Summers J, Jilbert AR, Yang W, Aldrich CE, Saputelli J, et al. (2003) Hepatocyte turnover during resolution of a transient hepadnaviral infection. Proc Natl Acad Sci U S A 100: 11652-11659.
55. Guo JT, Pryce M, Wang X, Barrasa MI, Hu J, et al. (2003) Conditional replication of duck hepatitis B virus in hepatoma cells. J Virol 77: 1885-1893.
56. Nawa T, Ishida H, Tatsumi T, Li W, Shimizu S, et al. (2012) Interferon-alpha suppresses hepatitis B virus enhancer II activity via the protein kinase C pathway. Virology 432: 452-459.
57. Robek MD, Wieland SF, Chisari FV, (2002) Inhibition of hepatitis B virus replication by interferon requires proteasome activity. J Virol 76: 3570-3574.
58. Xu C, Guo H, Pan XB, Mao R, Yu W, et al. (2010) Interferons accelerate decay of replication-competent nucleocapsids of hepatitis B virus. J Virol 84: 9332-9340.